Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Gomekli (mirdametinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

EMD Serono

Drug class:

MEK inhibitor

Related drugs:

NRAS mutation	Endometrial Cancer	NRAS mutation	Endometrial Cancer	mirdametinib Sensitive: C2 – Inclusion Criteria mirdametinib Sensitive : C2	mirdametinib Sensitive: C2 – Inclusion Criteria mirdametinib Sensitive : C2
NF1 deletion	Glioblastoma	NF1 deletion	Glioblastoma	mirdametinib Sensitive: C4 – Case Studies mirdametinib Sensitive : C4	mirdametinib Sensitive: C4 – Case Studies mirdametinib Sensitive : C4
KRAS mutation	Solid Tumor	KRAS mutation	Solid Tumor	mirdametinib + BGB-283 Sensitive: D – Preclinical mirdametinib + BGB-283 Sensitive : D	mirdametinib + BGB-283 Sensitive: D – Preclinical mirdametinib + BGB-283 Sensitive : D
PTEN deletion	Ovarian Cancer	PTEN deletion	Ovarian Cancer	mirdametinib + PF-04691502 Sensitive: D – Preclinical mirdametinib + PF-04691502 Sensitive : D	mirdametinib + PF-04691502 Sensitive: D – Preclinical mirdametinib + PF-04691502 Sensitive : D
KRAS G12D	Ovarian Cancer	KRAS G12D	Ovarian Cancer	mirdametinib + PF-04691502 Sensitive: D – Preclinical mirdametinib + PF-04691502 Sensitive : D	mirdametinib + PF-04691502 Sensitive: D – Preclinical mirdametinib + PF-04691502 Sensitive : D
KRAS mutation	Colon Cancer	KRAS mutation	Colon Cancer	PF-05212384 + mirdametinib Sensitive: D – Preclinical PF-05212384 + mirdametinib Sensitive : D	PF-05212384 + mirdametinib Sensitive: D – Preclinical PF-05212384 + mirdametinib Sensitive : D
PIK3CA mutation	Colon Cancer	PIK3CA mutation	Colon Cancer	PF-05212384 + mirdametinib Sensitive: D – Preclinical PF-05212384 + mirdametinib Sensitive : D	PF-05212384 + mirdametinib Sensitive: D – Preclinical PF-05212384 + mirdametinib Sensitive : D
NF1 deletion	Acute Myelogenous Leukemia	NF1 deletion	Acute Myelogenous Leukemia	mirdametinib Resistant: D – Preclinical mirdametinib Resistant : D	mirdametinib Resistant: D – Preclinical mirdametinib Resistant : D
RASGRP1 overexpression	Acute Myelogenous Leukemia	RASGRP1 overexpression	Acute Myelogenous Leukemia	mirdametinib Sensitive: D – Preclinical mirdametinib Sensitive : D	mirdametinib Sensitive: D – Preclinical mirdametinib Sensitive : D
KRAS mutation	Endometrial Cancer	KRAS mutation	Endometrial Cancer	mirdametinib Sensitive: D – Preclinical mirdametinib Sensitive : D	mirdametinib Sensitive: D – Preclinical mirdametinib Sensitive : D
HRAS mutation	Endometrial Cancer	HRAS mutation	Endometrial Cancer	mirdametinib Sensitive: D – Preclinical mirdametinib Sensitive : D	mirdametinib Sensitive: D – Preclinical mirdametinib Sensitive : D
miR-135-b expression	Pancreatic Cancer	miR-135-b expression	Pancreatic Cancer	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D